Introduction
An emerging biopharmaceutical company based in India, which had made significant strides in the development of innovative vaccines and treatments, sought to broaden its market presence and improve its competitive positioning both domestically and internationally. While the company had a solid product portfolio, it faced substantial challenges in identifying strategic partnership opportunities and navigating the complex healthcare landscape. These challenges included difficulties in forming relationships with governments, international non-governmental organizations (NGOs), and other key stakeholders, as well as an unclear understanding of how to expand its reach into new markets.
Background
The biopharmaceutical industry in India is highly competitive, with numerous companies vying for global market share. To break through these barriers and effectively scale its operations, the company needed comprehensive support in identifying and evaluating opportunities to partner with relevant healthcare stakeholders. This included forging partnerships that could provide access to funding, clinical trial opportunities, distribution networks, and regulatory support. In short, the company needed assistance in navigating a highly competitive, heavily regulated, and increasingly globalized market. To help them achieve this goal, the company engaged DBMR (Data Bridge Market Research), a global leader in market research and consulting services. The goal was to leverage DBMR’s research expertise to identify key players in the healthcare ecosystem, evaluate partnership opportunities, and guide the company in enhancing its competitive advantage.
The increasing demand for accurate and rapid molecular diagnostic tests has fueled significant growth in the molecular diagnostics market, especially PCR-based technologies. PCR is widely used for various applications such as disease detection, genetic research, and forensic science. However, many laboratories rely on open PCR systems, which are not always compatible with proprietary reagents offered by manufacturers of closed PCR systems. Open PCR platforms, which are often more cost-effective and customizable, present a unique opportunity for diagnostic companies to develop reagents that can serve a broader market. In this case, a leading molecular diagnostic provider sought DBMR’s expertise to evaluate the potential for creating PCR reagents that could be used on open PCR systems. The requirements included a detailed analysis of the regional market dynamics, sales volume, market share, and the installed base of PCR equipment to understand how to position their reagents effectively in a competitive and fragmented market.
